IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Mylan to Buy Merck KGaA’s Generics Unit for $6.7 Billion

1:39 PM MDT | July 25, 2007 | Alex Scott

Mylan Laboratories (Canonsburg, PA) says it has agreed to buy Merck KGaA’s generic pharmaceuticals business for €4.9 billion ($6.7 billion) in cash. The sale price is in line with market expectations (CW, May 9, p. 6). Merck KGaA’s generics unit generated sales in 2006 of €1.8 billion, placing it fourth in the market behind Barr Pharmaceuticals (Woodcliff Lake, NJ), Novartis, and Teva Pharmaceutical Industries (Petach Tikva, Israel). Mylan and the Merck KGaA business will have a combined annual Ebitda of about $1 billion and sales of about...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa